Axitinib – Treatment for Advanced Renal Cell Carcinoma
Inlyta (axitinib) was developed by Pfizer for treating advanced renal cell carcinoma (ARCC) and hepatocellular carcinoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Kidney Cancer | Liver Cancer | Pfizer | Pharmaceuticals | Renal Cell Carcinoma